BioWorld

April 16, 2008

Roche Buying Privately Held Piramed for $160M Up Front

Less than five years after its founding, privately held Piramed Ltd. agreed to be acquired by Roche Holdings Ltd. for $160 million up front in one of the few recent deals to stand out in the slumping UK biotech sector. (BioWorld Today) Read More

Genentech, Biogen Idec's Rituxan Misses Lofty Mark in MS Trial

At AACR, Discussions on a Faster Road to Beacons

Aileron Raises $10M to Pursue Stapled Peptides Therapeutics

Other News To Note

AACR Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...

Janssen Pharmaceutica reports new TMEM175 activators

BioWorld Science

Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...